# Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

> **NCT04338243** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Haihe Biopharma Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Negative T790M Mutation and Met Amplification

## Interventions

- **DRUG:** Glumetinib

## Key facts

- **NCT ID:** NCT04338243
- **Lead sponsor:** Haihe Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-18
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04338243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04338243, "Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04338243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*